http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#Head http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#assertion http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#provenance http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#pubinfo http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#assertion http://purl.obolibrary.org/obo/DOID_3319 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_3319 http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00877 http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#association http://www.w3.org/2000/01/rdf-schema#label rapamune is an mtor inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged 13 years receiving renal transplants 1 1 1 1 1 1 1 2 14 3 rapamune is an mtor inhibitor indicated for the treatment of patients with lymphangioleiomyomatosis 1 3 rapamune sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants in patients at low to moderate immunologic risk see dosage and administration 2 2 in patients at high immunologic risk see dosage and administration 2 3 clinical studies 14 3 cyclosporine withdrawal has not been studied in patients with banff grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawal those who are dialysis dependent those with serum creatinine 4 5 mg dl black patients patients of multi organ transplants secondary transplants or those with high levels of panel reactive antibodies see clinical studies 14 2 in patients at high immunologic risk see clinical studies 14 3 in pediatric patients see adverse reactions 6 5 clinical studies 14 6 the safety and efficacy of de novo see warnings and precautions 5 12 the safety and efficacy of conversion from calcineurin inhibitors to rapamune see clinical studies 14 4 rapamune sirolimus is indicated for the treatment of patients with lymphangioleiomyomatosis lam http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00877 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#provenance http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#pubinfo http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#sig http://purl.org/nanopub/x/hasSignature Xhiiavj2pgKsJIxRKis5junrbqLT2eqDwvFVD+0uEE9aDz67NqZmJEIrGj1Szw1dsaZNiIxn9Xvqx14xyg1QoYdkBy0b6jt/qvHU/8FJaGovTftYzqoCglTLrX1ZDE+Gm4gCZz+hr1Vk77A4JC3YDu2egc4i/79sYtnH/ARZ+7s= http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews http://purl.org/dc/terms/created 2021-07-03T15:29:06.847+02:00 http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs